In this cross-sectional, national and multicenter study, the main objective is to determine the prevalence of multi-drug resistant viruses (i.e., viruses that are resistant or possibly resistant to at least one antiretroviral drug from four different therapeutic classes: NRTI, NNRTI, PI, INSTI) among people with HIV 1 (PWH) experiencing virological failure.
Patient (male or female) 18 years of age or older.
Patient who has given his or her consent to participate in the study.
Patient on antiretroviral therapy for at least six months, with a plasma viral load (VL) greater than 50 copies/mL on at least two consecutive measurements.
Patients opposed to the use of their data.
Population of people living with HIV (PLHIV) in virological failure, the proportion of participants with virus resistant or possibly resistant to at least one antiretroviral agent from 4 different therapeutic classes: nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse trancriptase inhibitor (NNRTI), protease inhibitor (PI) and integrase inhibitor (INSTI).
Other
Other
Not listed
Drug resistance-associated mutations are those defined in the current ANRS algorithm (https://hivfrenchresistance.org/hiv-french-resitance-tables-of-rules/) and in the current Stanford algorithm (http://hivdb.stanford.edu) at the time of analysis.
Genotypic resistance to an antiretroviral drug will be interpreted using these two algorithms. Resistance to a therapeutic class will be defined as a resistance, or possible resistance, to all drugs in the class.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
